GMP Certified / Valsartan Dispersible Tablets 80mg

• Customization: Available
• Quality Standard: Bp, USP
• Ctd Dossier: Ready
• Model NO.: Tablet
• Documentation: Copp, COA
• Factory Certification: GMP
• Transport Package: Carton
• Specification: 80mg
• Trademark: Sinolead
• Origin: China
• Production Capacity: 100, 000, 000 Per Year

Product Description

Product Description

Generic Name	Valsartan dispersible Tablets
Strength	80mg
Packing	14 tablets /box
Origin	China

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Valsartan dispersible Tablets 80mg

Character:
This product is white.

Indications:
Treatment of mild and moderate essential hypertension.

Matters needing attention:
Low sodium and/or low blood volume
In rare cases, patients with severe sodium deficiency and/or low blood volume (e.g., large doses of diuretics) may experience symptomatic hypotension at the beginning of treatment with this product. Low sodium and/or low blood volume should be corrected, or diuretics reduced, before medication. If hypotension occurs, the patient should be placed on his or her back and given intravenous saline if necessary. Blood pressure stabilized after the resumption of this product treatment.
Renal artery stenosis
12 patients with secondary renal vascular hypertension caused by unilateral renal artery stenosis took this product for 4 days, and there was no significant change in renal hemodynamics, creatinine, urea nitrogen (BUN). Because other drugs acting on RAAS may raise BUN and creatinine in patients with unilateral or bilateral renal artery stenosis, monitoring is recommended to ensure safety.
Renal insufficiency
Patients with renal insufficiency do not need to adjust the dose.
Liver dysfunction
Patients with hepatic insufficiency do not need to adjust the dose.
The dose of valsartan should not exceed 80mg/ day in patients with mild to moderate hepatic insufficiency.
Valsartan is primarily excreted from the bile in prototype form, with reduced excretion in patients with biliary obstruction (see pharmacokinetics), and particular caution should be exercised in such patients.
As with other antihypertensive drugs, patients should be careful when driving and operating machinery.

Pharmacology and toxicology:
Action mechanism
The activator of the renin-angiotensin-aldosterone system (RAAS) is angiotensin II, which is formed by angiotensin I under the action of angiotensin-converting enzyme (ACE). Angiotensin II binds to specific receptors on cell membranes of various tissues. It has a variety of physiological effects, including direct or indirect involvement in blood pressure regulation. Angiotensin II is a powerful vasoconstricting substance, which has a direct pressor effect, and can also promote sodium reabsorption and stimulate aldosterone secretion.
Valsartan is an orally effective specific angiotensin (AT) receptor antagonist that selectively acts on the AT1 receptor subtype, producing all known effects. The AT2 receptor subtype was not associated with cardiovascular effects. Valsartan does not have any partial agonist activity on the AT1 receptor. Valsartan has a 20,000 times stronger affinity with the AT1 receptor than the AT2 receptor.
ACE converts angiotensin I to angiotensin II and degrades bradykinin. Angiotensin II receptor antagonist Valsartan has no inhibitory effect on ACE and does not cause bradykinin or substance P retention, so it does not cause cough. Clinical trials comparing valsartan with ACE inhibitors confirmed that the incidence of dry cough in valsartan group (2.6%) was significantly lower than that in ACE inhibitor group (7.9%)(P[0.05). In a clinical trial of patients who developed dry cough after receiving ACE inhibitors, 19.5%, 19.0%, and 68.5% of patients in the valsartan, diuretic, and ACEI groups developed cough, respectively (P<0.05). Valsartan has no effect on other hormone receptors or ion channels known to play an important role in cardiovascular regulation.
Drug effect
Valsartan lowers elevated blood pressure without affecting heart rate.
For most patients, a single dose of oral antihypertensive effect within 2 hours, 4-6 hours to reach the peak effect, the antihypertensive effect maintained until more than 24 hours after taking the drug. The maximum antihypertensive effect is achieved after 2-4 weeks of treatment and is maintained during long-term treatment. Combined with thiazide diuretics can further significantly enhance the antihypertensive effect.
Abrupt termination of valsartan treatment did not cause high blood pressure "rebound" or other side effects.
Valsartan did not affect total cholesterol, triglycerides, blood sugar, and uric acid levels in hypertensive patients.

Storage:
Seal and store in a dry place (no more than 30ºC).